PEDIATRIC ONCOLOGY GROUP

这项提议代表了支持继续参与的请求 在儿科肿瘤学小组(POG)。这项合作研究是 致力于化疗药物的研究等新的创新 急性白血病和其他肿瘤疾病的治疗方法 童年的记忆。显著缓解和延长了生存时间 在临床药理学方面取得了成就并做出了贡献。 然而，这些研究的真正目标是根除 通过治疗获得的肿瘤疾病。正在设计的研究旨在反映 对肿瘤细胞的攻击强度越来越大。合作社 成组技术允许以合理大小的一系列快速评估 在化疗方面很有希望的线索。这些线索或新方法通常是 根据该小组自己在临床肿瘤学方面的工作结果提出的建议。 因此，一项完整的议定书往往建议在#年探索新途径。 新协议。POG还领导了对猪瘟免疫表型的研究 急性淋巴细胞性白血病与预后的相关性及设计 相应的适当治疗方案。 儿科血液科/肿瘤科 加州大学圣地亚哥分校的儿科学专业有10年 参与癌症和白血病B组的合作小组研究 在1980年加入POG之前。我们是世界上最大的 患者登记表中对团体方案研究的贡献者。在最后一次 4年来(1984年11月-1988年11月)，我们已经进入了457例患者组 礼仪研究。从1988年5月到1989年5月，有 110例患者从UCSD进入。龚方雄博士和余丽娟博士均担任主席 团体治疗方案(白血病、霍奇金氏病和新药)。 余博士的实验室也是 肿瘤标志物脱氧辅酶A霉素GD2的药理研究 神经母细胞瘤。韦恩·斯普鲁斯博士积极参与团体方案 关于骨髓移植。赫克托·詹姆斯医生治疗脑瘤 委员会审议阶段。威廉·托马斯博士是该方案的研究协调员。 生殖细胞肿瘤的治疗。John Fontanesi博士是驱动力 团体礼仪研究中神经心理测试设计的背后 低辐射小脑星形细胞瘤和视路肿瘤。我们计划 继续积极参与POG活动的各个阶段。

This proposal represents a request to support continued participation in the Pediatric Oncology Group (POG). This cooperative research is devoted to the investigation of chemotherapeutic and other new innovative approaches to the treatment of acute leukemia and other neoplastic diseases of childhood. Significant palliation and prolongation of survival has been achieved and contributions have been made in clinical pharmacology. However, the real objective of these studies is the eradication of neoplastic diseases by treatment. Studies are being designed to reflect an increasing intensity of attack on the neoplastic cell. The cooperative group technique permits prompt evaluation in series of reasonable size of promising leads in chemotherapy. These leads or new approaches are often suggested by the results of the group's own work in clinical oncology. Thus, a completed protocol often suggests new avenues to be explored in new protocols. POG also led in the investigation of immunophenotyping of acute lymphoblastic leukemia, correlating it with prognosis and designing appropriate treatment protocols accordingly. The Division of Pediatric Hematology/Oncology in the Department of Pediatrics at the University of California, San Diego had a 10 year involvement in cooperative group studies with Cancer and Leukemia Group B prior to joining forces with POG in 1980. We have been one of the major contributors in patient registry to group protocol studies. In the last 4 years (Nov. 1984 - Nov. 1988), we have entered 457 patients on Group protocol studies. For the year from May 1988 through May 1989, there were 110 patients entered from UCSD. Both Drs. Faith Kung and Alice Yu chair group therapeutic protocols (-leukemia, Hodgkin's disease and new agents). Dr. Yu's laboratory also serves as the group reference laboratory for the study of the pharmacology of deoxycoformycin GD2, a tumor marker for neuroblastoma. Dr. Wayne Spruce is actively involved with group protocols on bone marrow transplantation. Dr. Hector James serves on the Brain Tumor Committee. Dr. William Thomas is a study coordinator for the protocol on the treatment of germ cell tumors. Dr. John Fontanesi is the driving force behind the design of neuropsychological testing for group protocol studies on low rade cerebellar astrocytomas and visual pathway tumors. We plan to continue our active participation in all phases of POG activities.